LRRCC1, or Leucine-Rich Repeat and Coiled-Coil Domain-Containing 1, is a protein that, as its name suggests, contains domains that are rich in leucine residues and characterized by a coiled-coil structure. The leucine-rich repeat (LRR) is a protein structural motif that typically forms an α/β horseshoe fold, which is involved in protein-protein interactions. LRR motifs are known for their role in the formation of complexes, often being involved in various signaling pathways and cellular processes due to their ability to facilitate specific molecular interactions.
The coiled-coil domain is a structural motif that mediates the oligomerization of proteins, which is the process by which proteins form complexes through dimerization or higher-order associations. This domain is characterized by heptad repeats of amino acids where the first and fourth positions are typically occupied by hydrophobic residues, often leucine, which drive the coiling of α-helices around each other. Coiled-coil domains are fundamental in the formation of the cytoskeleton and various motor proteins, as well as in transcription factors and vesicle transport.In the context of LRRCC1, the combination of LRR and coiled-coil domains suggests a multifunctional role. LRRCC1 could be implicated in cellular signaling, acting as a scaffold for the assembly of multiprotein complexes, and may play a role in the regulation of various pathways through its mediated interactions. Additionally, the coiled-coil region implies a potential role in the structural organization within the cell, possibly influencing cytoskeletal dynamics or intracellular trafficking.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A potent inhibitor of phosphoinositide 3-kinases (PI3K), which may indirectly affect LRRCC1-related signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Another PI3K inhibitor, used to study the role of PI3K in various cellular processes that might intersect with LRRCC1 functions. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
This compound inhibits p38 MAP kinase, potentially affecting stress response pathways that could intersect with LRRCC1 functions. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor, affecting cellular growth and proliferation pathways, possibly impacting LRRCC1's indirect roles. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor, which may alter cytoskeletal dynamics and potentially intersect with LRRCC1-related processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An inhibitor of MEK, which may indirectly affect signaling pathways involving LRRCC1. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which could modify cellular stress responses potentially linked to LRRCC1. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor, could indirectly affect protein degradation pathways related to LRRCC1. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
A tyrosine kinase inhibitor, potentially impacting signaling pathways that may intersect with LRRCC1 functions. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Another tyrosine kinase inhibitor, which could indirectly affect pathways related to LRRCC1. | ||||||